Aldeyra Therapeutics Stock News

Equities research analysts expect Aldeyra Therapeutics, Inc (NASDAQ:ALDX) to post earnings of ($0.34) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Aldeyra Th

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) saw a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 574,100 shares, a decrease of 8.7% from t

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that senior management will be presenting and hosting 1x1 meetings at the followin

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immun

Two Sigma Advisers LP lifted its stake in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 239.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today a

Shares in Aldeyra Therapeutics (ALDX) are climbing 10% in Tuesday’s pre-market trading following a SEC filing showing that Joseph Edelman’s Perceptive Advisors now holds a 19.1% in the company.Ac

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will discuss the company’s clinical programs in anterior a

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will discu

Aldeyra Therapeutics, Inc (NASDAQ:ALDX)’s stock price was down 7.3% during trading on Friday . The stock traded as low as $4.79 and last traded at $4.82, approximately 2,173,900 shares were traded d

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filin

Oppenheimer analyst Justin Kim assigned a Buy rating to Aldeyra Therapeutics (ALDX – Research Report) today and set a price

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immun

JPMorgan Chase & Co. boosted its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 756.6% during the first quarter, according to the company in its most recent 13F filing with the Securities and

Every investor in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) should be aware of the most powerful shareholder groups...